AtOM-CF Study (Part 1)
Research type
Research Study
Full title
How can Adherence to Oral Medication be improved for the benefit of people with cystic fibrosis (AtOM-CF Study) (Part 1).
IRAS ID
300925
Contact name
Nicola J Shaw
Contact email
Sponsor organisation
University of Leeds
Duration of Study in the UK
2 years, 1 months, 30 days
Research summary
Cystic fibrosis (CF) is a genetic illness that affects more than 10,500 people in the UK. It is life limiting, with average life expectancy around 47 years. Until recently treatment could only help control and reduce the effects of mucus build up.
A new treatment is now available - tablets called modulators. They improve symptoms, stabilise the illness and prevent further damage to organs such as the lungs. People taking modulators as intended should live longer and with fewer periods of severe illness.
Despite the positive health benefits, it appears that some people do not take modulators as prescribed. This not only affects the life of the person with CF, but also NHS resources as frequent admissions to hospital are needed. Understanding the reasons for this are essential to maximise the health benefits of this new treatment.
This study aims to find new ways to support and encourage the regular taking of this life-long treatment, as well as other regular medication. The study will be carried out in three parts over 3 years.
In the first part of the study, we will measure how well people take the new modulator medicines in adults (> 16 years) attending two CF centres in England (Leeds and Newcastle), who are prescribed a modulator. We will also find out about the problems these people have using prescribed medication, using something called the ' Living with Medicines Questionnaire’. It will take around 30 mins to complete at a time convenient to the patient.
Results will highlight in which areas the patients experience medication burden. This will allow support to be targeted to maximise the benefits. The issues will be explored in-depth in Part 2 of the study where interviews will be conducted.
This study is funded by Health Education England/NIHR as a clinical doctoral research fellowship.
REC name
HSC REC B
REC reference
22/NI/0065
Date of REC Opinion
30 Mar 2022
REC opinion
Further Information Favourable Opinion